A naukri.com initiative
Eu-Startups
1d
249
Swiss MedTech company Comphya raises €8 million to tackle erectile dysfunction with new device
- Swiss MedTech company Comphya SA has raised €8 million in an oversubscribed Series A financing round to develop an implantable neurostimulation therapy for erectile dysfunction (ED) that is unresponsive to medication.
- Comphya is working on CaverSTIM, an implantable device that aims to restore erectile function by stimulating the nerves responsible for penile erection. The company's goal is to provide a more effective and less invasive solution for men with ED, especially those who have undergone prostate cancer treatment.
- The funding will support the launch of a U.S. pilot study at Johns Hopkins and help prepare for a pivotal clinical trial in 2026. Early results from a study in Australia have shown promising safety and efficacy signals, indicating the potential of CaverSTIM to improve post-prostatectomy care.
- Comphya's neurostimulator system marks a significant advancement in addressing erectile dysfunction, offering patients a potentially more comfortable and effective alternative to current therapies like injections or implants. The company's recent leadership changes aim to guide its future clinical growth and strategic execution.
Read Full Article
14 Likes
For uninterrupted reading, download the app